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background: Over the last few years, the use of phosphodiesterase type 5 (PDE5) inhibitors has been expanded to management of various 
cardiovascular disorders. We investigated the ability of udenafil, a newly developed long-acting PDE5 inhibitor, to improve functional capacity and 
hemodynamic status in a cohort of systolic heart failure (SHF) patients.
methods and results: Stable, chronic SHF patients were randomly assigned to placebo (20 patients) or udenafil at a dose of 50 mg twice per 
day (21 patients) for the first 4 weeks followed by 100 mg twice daily for the next 8 weeks. Patients underwent cardiopulmonary exercise testing 
before and after treatment. The change in peak VO2 from baseline, the primary end point, was greater in the udenafil group (3.47±1.07 mL x kg(-1) 
x min(-1)) than in the placebo group (-0.36±0.56 mL x kg(-1) x min(-1); P=0.01). Udenafil treatment also was associated with left ventricular (LV) 
remodeling. LV volume was smaller in the udenafil group compared with the placebo group (baseline LV end-systolic volume, 148ml for udenafil 
versus 145ml for placebo group; P= NS.; 3month later LV end-systolic volume, 110ml for udenal versus 132ml for placebo, respectively; P< 0.05). 
LV ejection fraction was greater in the udenafil group than in the placebo group (36% for udenafil versus 31% for placebo, P< 0.05) without mean 
arterial pressure, heart rate, or systemic vascular resistance. Udenafil treatment also was associated with improvement in 6-minute walk distance 
(33 m versus placebo; P=0.04) and Minnesota Living With Heart Failure score (-10 versus placebo; P=0.01). Subjects in the udenafil group 
experienced fewer hospitalizations for HF and a higher incidence of than those in the placebo group without incurring excess serious adverse events.
conclusions: Phosphodiesterase 5 inhibition with udenafil improves exercise capacity and quality of life in patients with chronic SHF.
